Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Pharmalittle: We're reading about a 'miracle' HIV drug program, Lilly going after compounders, and more

A U.S. court sided with the the Department of Health and Human Services in a fight over a Vertex Pharmaceuticals fertility program

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

Eli Lilly is coming after makers of copycat versions of Zepbound

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.Read more...

Chicago – Although semaglutide and tirzepatide can significantly reduce body weight and protect many obese people from type 2 diabetes and cardiovascular disease, a cost-benefit analysis in JAMA Health Forum (2025; DOI: 10.1001/jamahealthforum.2024.5586) is negative. The less effective, but significantly cheaper...

GPs can prescribe tirzepatide to priority patient groups from June

General practitioners will be able to prescribe the weight loss injection tirzepatide (Mounjaro) to “prioritised patient cohorts” from 23 June, NHS England has said. New interim commissioning guidance instructs integrated care boards (ICBs) to meet the funding costs of tirzepatide and sets out a phased implementation plan for the next three years.1 Last June the National Institute for Health and Care Excellence (NICE) published draft guidance re…

GPs to prescribe tirzepatide from June in phased primary care rollout

GPs will be able to start prescribing the weight loss injection tirzepatide (Mounjaro) to a defined group of patients from June, according to new NHS England guidance.